Hong Kong stock movement: HAIXI PHARMA fell 16.52%, can the analyst target price of HKD 298.28 reverse the decline?

Hong Kong Stock Movement HAIXI PHARMA fell 16.52%. Based on recent key news: On April 25, SWS Res analysts maintained a buy rating for Fujian Haixi Pharmaceutical and set a target price of HKD 298.28. The company's stock closed at HKD 213.00 yesterday, and analysts unanimously believe the stock is a moderate buy with a target price of HKD 298.28. On April 25, Shenwan Hongyuan analysts maintained a buy rating for Fujian Haixi Pharmaceutical and set a target price of HKD 298.28. The company's stock closed at HKD 237.60 yesterday, and analysts unanimously believe the stock is a moderate buy with a target price of HKD 298.28. Analysts unanimously believe the stock is a moderate buy with a target price of HKD 298.28. Stocks with High Trading Volume in the Industry CSPC Pharmaceutical Group fell 1.14%. Based on recent key news: On April 28, CSPC Pharmaceutical Group announced that its subsidiary CSPC Innovation's first-quarter loss widened to HKD 93.85 million, an increase compared to the same period last year, mainly due to increased shareholding, higher R&D investment, and foreign exchange losses. This news put pressure on the stock price. Source: Zhitong Finance On April 27, CSPC Pharmaceutical Group's SYS6010 drug clinical trial results were poor, raising doubts about its commercialization prospects. Additionally, the company's business concentration is relatively high, making it vulnerable to policy shocks in a single field, leading to market concerns about its future performance. Source: Zhitong Finance On April 27, CSPC Pharmaceutical Group announced that despite revenue growth, net losses widened year-on-year, and investment and cost pressures may affect short-term returns. Source: Zhitong Finance. The pharmaceutical industry faces policy risks and requires attention. China Biologic Products fell 0.90%. Based on recent key news: On April 27, China Biologic Products announced the repurchase of 1.81 million shares, costing HKD 10.0473 million. This move shows the company's confidence in its own value, which typically supports the stock price, but it failed to prevent the stock price from falling. No other significant news recently. The pharmaceutical industry has been volatile recently and requires attention to policy changes. WuXi AppTec rose 6.95%. Based on recent key news: On April 27, WuXi AppTec announced its first-quarter 2026 performance, with revenue of HKD 1.802 billion, a year-on-year increase of 16.91%; net profit of HKD 304 million, a year-on-year decrease of 6.82%. The decrease in net profit was mainly due to high foreign exchange losses caused by the appreciation of the RMB. Source: Zhitong Finance On April 27, Goldman Sachs released a research report maintaining a "buy" rating for WuXi AppTec, believing that the performance cycle of CDMO companies is robust, with increased exposure to future and commercialization projects. Source: Zhitong Finance On April 28, WuXi AppTec's announcement showed that revenue from emerging businesses grew by 74.07% in the first quarter, mainly driven by strong growth in the chemical macromolecule and biological macromolecule business segments. Source: Economic Information Daily. The pharmaceutical industry cycle is robust, and exchange rate fluctuations have a significant impact Stocks Ranked Among the Top by Market Capitalization in the Industry Hengrui Medicine rose by 0.30%. Based on recent key news: On April 27, Hengrui Medicine partnered with Kailera to advance its GLP-1 product portfolio, expecting to enjoy global value appreciation from innovative assets in the next 3-5 years, driving up the stock price. Source: Zhitong Finance On April 27, CMB International raised Hengrui Medicine's target price to HKD 74, maintaining a "Neutral" rating, as the first-quarter performance exceeded expectations, with innovative drug sales revenue increasing by 26% year-on-year. Source: Zhitong Finance On April 25, Hengrui Medicine's financial leverage is controllable, asset quality is high, and R&D investment is significant, supporting the company's long-term development. Source: Barron's The innovative drug industry is at a critical point of qualitative change, with high volatility risks